PGI39 Budegt Impact Analysis of HCV Therapy Cost After Boceprevir Addition to Standard Therapeutic Regime

Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.788
https://www.valueinhealthjournal.com/article/S1098-3015(12)02501-6/fulltext
Title : PGI39 Budegt Impact Analysis of HCV Therapy Cost After Boceprevir Addition to Standard Therapeutic Regime
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02501-6&doi=10.1016/j.jval.2012.08.788
First page : A333
Section Title : Gastrointestinal Disorders
Open access? : No
Section Order : 300
Categories :
Tags :
Regions :
ViH Article Tags :